LGVN Form 4: Lisa Locklear Acquires 11,766 Shares and 29,415 Warrants
Rhea-AI Filing Summary
Lisa Locklear, identified on the Form 4 as Chief Financial Officer and a director of Longeveron Inc. (LGVN), made a direct purchase on 08/11/2025 of 11,766 shares of Class A common stock. Each purchased share was accompanied by two and one-half Class A common warrants, for a total of 29,415 warrants, and the combined purchase price for each share plus accompanying warrants was $0.85. Following the reported transaction, Ms. Locklear directly beneficially owned 250,964 shares of Class A common stock.
The warrants are shown with an exercise/conversion price of $0.85 and an expiration date of 08/11/2027, and the reported holdings and transactions are recorded as direct ownership on the Form 4.
Positive
- Insider purchase recorded: 11,766 Class A shares acquired directly on 08/11/2025
- Accompanying warrants: 29,415 Class A warrants received (2.5 warrants per share) with exercise price $0.85
- Increased direct ownership to 250,964 Class A common shares following the transaction
Negative
- None.
Insights
TL;DR: CFO purchased common stock with bundled warrants at $0.85, raising direct holdings to 250,964 shares; transaction reported on Form 4.
The filing shows a direct purchase code (P) dated 08/11/2025 for 11,766 Class A shares bundled with two and one-half warrants per share (29,415 warrants total). The combined per-share purchase price, which also reflects the warrants, is reported as $0.85. Post-transaction direct common stock ownership is 250,964 shares. These are explicit, verifiable facts from the Form 4; the document does not disclose cash paid beyond the combined price, nor context on proportionality versus total outstanding shares.
TL;DR: Reported insider purchase filed under Section 16; ownership updated and warrants disclosed, with no other governance changes reported.
The Form 4 identifies Lisa Locklear as both an officer (Chief Financial Officer) and a director and records the transaction as direct beneficial ownership. The derivative instrument details are explicit: warrants exercisable beginning 08/11/2025, expiring 08/11/2027, with an exercise/conversion price of $0.85. The filing includes the standard Form 4 disclosures; it does not include amendments, sales, or changes to board composition.